- Home
- UFCS vs ABUS Comparison
UFCS vs ABUS Comparison
Compare UFCS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFCS
- ABUS
- Stock Information
- Founded
- UFCS 1946
- ABUS 2005
- Country
- UFCS United States
- ABUS United States
- Employees
- UFCS N/A
- ABUS N/A
- Industry
- UFCS Property-Casualty Insurers
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- UFCS Finance
- ABUS Health Care
- Exchange
- UFCS Nasdaq
- ABUS Nasdaq
- Market Cap
- UFCS 922.3M
- ABUS 828.9M
- IPO Year
- UFCS N/A
- ABUS N/A
- Fundamental
- Price
- UFCS $37.44
- ABUS $4.31
- Analyst Decision
- UFCS Buy
- ABUS Strong Buy
- Analyst Count
- UFCS 2
- ABUS 2
- Target Price
- UFCS $33.00
- ABUS $5.00
- AVG Volume (30 Days)
- UFCS 125.9K
- ABUS 1.1M
- Earning Date
- UFCS 11-04-2025
- ABUS 11-13-2025
- Dividend Yield
- UFCS 1.72%
- ABUS N/A
- EPS Growth
- UFCS 118.04
- ABUS N/A
- EPS
- UFCS 4.24
- ABUS N/A
- Revenue
- UFCS $1,353,781,000.00
- ABUS $14,606,000.00
- Revenue This Year
- UFCS $12.34
- ABUS $138.02
- Revenue Next Year
- UFCS $14.56
- ABUS N/A
- P/E Ratio
- UFCS $8.80
- ABUS N/A
- Revenue Growth
- UFCS 12.12
- ABUS 116.64
- 52 Week Low
- UFCS $24.11
- ABUS $2.71
- 52 Week High
- UFCS $37.48
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- UFCS 67.91
- ABUS 45.05
- Support Level
- UFCS $36.03
- ABUS $4.08
- Resistance Level
- UFCS $37.35
- ABUS $4.42
- Average True Range (ATR)
- UFCS 1.10
- ABUS 0.23
- MACD
- UFCS 0.02
- ABUS -0.05
- Stochastic Oscillator
- UFCS 90.11
- ABUS 28.48
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.